Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD
Phase 3 data show survodutide normalized liver fat in 61% of patients with MASLD while reducing weight, visceral fat, and metabolic risk factors.
Lee Kaplan, MD, PhD
Advertisement
Lee Kaplan, MD, PhD, is the director of The Obesity and Metabolism Institute, Massachusetts General Hospital, in Boston, MA.
Articles by Lee Kaplan, MD, PhD
ADA 2026 data show survodutide cut visceral fat by 34% and liver fat by 63%, suggesting metabolic benefits beyond weight loss in phase 3 trials.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO
2
GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis
3
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss
4
Childhood Influenza Vaccine Rates Decreased From 2017 to 2023
5